These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2444993)

  • 21. Differential inhibition of prostacyclin production and platelet aggregation by aspirin in humans.
    Masotti G; Galanti G; Poggesi L; Abbate R; Neri Serneri GG
    Adv Prostaglandin Thromboxane Res; 1980; 6():317-20. PubMed ID: 6992529
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapeutic effectiveness of prostaglandins (PGs) in peripheral vascular disease (PVD).
    Linet OI; Mohberg NR
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():307-10. PubMed ID: 2473609
    [No Abstract]   [Full Text] [Related]  

  • 23. The behaviour of various platelet function tests during long-term prostacyclin infusion in patients with peripheral vascular disease.
    Sinzinger H; Horsch AK; Silberbauer K
    Thromb Haemost; 1983 Dec; 50(4):885-7. PubMed ID: 6229898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease.
    Darius H; Kopp H; Mulfinger A; Spielberger M; Todt M; Schuster CJ; Meyer J
    Prog Clin Biol Res; 1989; 301():417-21. PubMed ID: 2508112
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.
    Maurin N
    Arzneimittelforschung; 1986 Aug; 36(8):1180-3. PubMed ID: 3096342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
    Jaschonek K; Renn W; Weisenberger H
    Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of halothane on platelet function.
    Dalsgaard-Nielsen J; Gormsen J
    Thromb Haemost; 1980 Dec; 44(3):143-5. PubMed ID: 7466741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of ciloprost (ZK 36 374): a chemically stable and biologically potent prostacyclin analog.
    Skuballa W; Vorbrüggen H
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():299-305. PubMed ID: 6189381
    [No Abstract]   [Full Text] [Related]  

  • 29. Proceedings: Refractoriness in blood platelets: effect of prior exposure to aggregating agents on subsequent aggregation responses.
    Evans RJ; Gordon JL
    Br J Pharmacol; 1974 May; 51(1):123P. PubMed ID: 4441772
    [No Abstract]   [Full Text] [Related]  

  • 30. Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.
    Mardla V; Kobzar G; Samel N
    Platelets; 2004 Aug; 15(5):319-24. PubMed ID: 15370103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet function as an indicator of adequate dialysis.
    Rabiner SF; Drake RF
    Kidney Int Suppl; 1975 Jan; (2):144-6. PubMed ID: 1057672
    [No Abstract]   [Full Text] [Related]  

  • 32. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterologous desensitization of platelet adenosine (A2) responses by iloprost.
    MacDermot J; Wilkins AJ; Edwards RJ
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():479-81. PubMed ID: 2444081
    [No Abstract]   [Full Text] [Related]  

  • 34. Monitoring of in-vivo platelet deposition in patients with peripheral vascular disease after different doses of prostaglandin I2 (PGI2).
    Strobl-Jäger E; Fitscha P; Kaliman J; Sinzinger H
    Prog Clin Biol Res; 1987; 242():403-7. PubMed ID: 3118387
    [No Abstract]   [Full Text] [Related]  

  • 35. Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation.
    Lidbury PS; Antunes E; de Nucci G; Vane JR
    Br J Pharmacol; 1989 Dec; 98(4):1275-80. PubMed ID: 2482103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet function in blood from the coronary sinus in patients with arteriosclerotic heart disease.
    Thaulow E
    Thromb Haemost; 1983 Oct; 50(3):629-32. PubMed ID: 6228029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease--a rebound phenomenon?
    Sinzinger H; Silberbauer K; Horsch AK; Gall A
    Prostaglandins; 1981 Jan; 21(1):49-51. PubMed ID: 7010457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hepoxilin stable analogue, PBT-3, inhibits primary, platelet-related hemostasis in whole blood measured in vitro with the PFA-100.
    Reynaud D; Clark D; Qiao N; Rand ML; Pace-Asciak CR
    Thromb Res; 2003; 112(4):245-8. PubMed ID: 14987919
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.
    Ghosh K; Nair S; Kulkarni B; Khare A; Shetty S; Mohanty D
    Platelets; 2003 Sep; 14(6):351-4. PubMed ID: 14602548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.